2022 Annual Meeting | Industry Therapeutic Update from Janssen Pharmaceuticals, Inc.: The Latest Considerations on S1P Receptor Modulators in the Treatment of Multiple Sclerosis

2022 Annual Meeting | Industry Therapeutic Update from Janssen Pharmaceuticals, Inc.: The Latest Considerations on S1P Receptor Modulators in the Treatment of Multiple Sclerosis – An Expert Discussion

Date Monday 04/04/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology, Multiple Sclerosis

Learning Objectives - This presentation will be led by Dr. Daniel Bandari, Dr. Bruce Hughes, Dr. Regina Berkovich, and Dr. Jeffrey Dunn
- Doors open at 7:00 PM PST. Presentation will be from 7:15 - 8:45 PST
- The presentation will be followed by a Live Q&A Session.
- Dinner will be provided
------------------------
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN.
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available 0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from Janssen Pharmaceuticals, Inc.: Treatment of Multiple Sclerosis: A Review of the Latest Advancement

Faculty Disclosures
Daniel Bandari, MD	No disclosure on file
Bruce L. Hughes, MD, FAAN	No disclosure on file
Regina Berkovich, MD, PhD	The institution of Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alexion, Biogen, Genentec, Mallincrodt, Sanofi, Novartis, . Dr. Berkovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Genentec, Sanofi, Merck . Dr. Berkovich has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion, Biogen, Sanofi, Merck, Mallincrodt . The institution of Dr. Berkovich has received research support from Biogen, Sanofi, Merck.
Jeffrey E. Dunn, MD, FAAN	Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics. Dr. Dunn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna Therapeutics. Dr. Dunn has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��